BACKGROUND Evolving Regulatory Pathways and Ethical Challenges in Accelerated Cancer Drug Approvals Recent updates to European pharmaceutical regulations have introduced accelerated and conditional approval pathways for marketing authorization, largely modeled after the U.S. Food and Drug Administration (FDA)’s expedited programs such as Accelerated Approval and Breakthrough Therapy Designatio...